AstraZeneca, with worldwide headquarters in Cambridge, UK, announced that it is consolidating some of its California staffers at The Cove at Oyster Point in South San Francisco.
Giving stimulants to kids with attention deficit hyperactivity disorder (ADHD) may not help them complete homework or get better grades, a small study suggests.
The Americas has become the first region in the world to be free of measles, following a 22-year vaccination drive against the disease which continues to infect tens of thousands of people globally, the Pan American Health Organization said.
Amgen’s multiple myeloma drug did not fare better than Takeda’s older therapy Velcade in a study involving patients who had not yet been treated for the disease.
Shares of Kite Pharma were up after the company’s CAR-T therapy KTE-C19 demonstrated a 39 percent response rate, including a complete response rate of one-third of patients with various forms of Non-Hodgkin’s Lymphoma after three months of treatment, the company announced.
Bristol-Myers Squibb will evaluate the use of its blockbuster immunotherapy Opdivo with an experimental drug from Nektar Therapeutics to treat multiple cancers.
After a strategic review of its portfolio after its acquisition of Baxalta, Shire has terminated two biosimilar deals: one with Momenta Pharmaceuticals and the other with Coherus Biosciences.
Sanofi SA said the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum.
There are 3 key facts life sciences companies need to know about real-time or near real-time medical claims data to support timely business decision-making.
Mylan NV faced questions about the profit on its EpiPen emergency allergy treatment, following a report that the company makes 60 percent more on the injector than it had told Congress.
Pfizer, which was considering a split into two companies for more than two years, said it would not do so because the move would not create any shareholder value.
Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.
An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain’s GW Pharmaceuticals to a record high.
Vela Diagnostics said its test for the Zika virus had received “emergency use authorization” from the U.S. Food and Drug Administration.
On the same day that Pfizer announced it would not break into two companies, Waltham, Mass.-based PerkinElmer announced that it was breaking into two separate companies.
Five months after its acquisition by McKesson Corp. was finalized as part of a $1.2 billion deal, North Carolina-based Biologics Inc. announced it was terminating 132 employees, the Triangle Business Journal reported.
The U.S. Food and Drug Administration approved Amgen’s biosimilar version of AbbVie’s top-selling arthritis drug Humira.
Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli.
Six international health experts, including four from Europe, are to compete to become the next director general of the World Health Organization (WHO) after its current leader Margaret Chan ends her tenure in June 2017.
United Parcel Service Inc. said it began testing the use of drones for emergency deliveries of medical supplies with a flight in rural Massachusetts, which the company hopes will eventually lead to federal approval of drones as a regular delivery option.